The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. Hemgenix, CSL’s one-time gene therapy for patients with hemophilia B, is experiencing a “temporary ...

The bottom line: We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades.

A global biopharmaceutical company has announced it will invest $1. 5 billion for a new manufacturing facility in Bradley, ...

Market volatility has pushed a number of high-quality stocks lower. Here’s how I’m thinking about this. The post CSL and ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Markets fared ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more surprising. The post What on earth's going on with the CSL share price? appeared ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...